Alzheimer's education not approved in EU
The European Medicines Agency has refused to approve a new drug for Alzheimer's disease in the EU.Vissanumab does not appear to be effective in treating adults with early-stage symptoms, the EMA says.The Alzheimer's charity was disappointed by the decision as thousands of people were left without tr
abnormal clots in the brains of people with Alzheimer's disease.
- The European Medicines Agency has refused to approve a new drug for Alzheimer's disease in the EU.
- Vissanumab does not appear to be effective in treating adults with early-stage symptoms, the EMA says.
The Alzheimer's charity was disappointed by the decision as thousands of people were left without treatment. The first new drug in 20 years - received controversial approval in the United States in June.
At the time, many scientists said there was little evidence in the test that it was helpful, even though it did target amyloid, a protein that forms abnormal clots in the brains of people with Alzheimer's disease.
Biogen, the drug's manufacturer, may request that the EMA's decision be reviewed in the next two weeks. After that, it is not known whether the company will file a separate application for approval with the UK regulator, MHRA.
Disclaimer: The opinions expressed within this article are the personal opinions of the author. The facts and opinions appearing in the article do not reflect the views of 25hrNews and 25hrNews does not assume any responsibility or liability for the same.
(+91) 8081113111
pr@25hrnews.com
